Lupin has launched Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vials, having received an approval from the United States Food and Drug Administration (USFDA) earlier.
The company’s Doxercalciferol Injection, is the therapeutic generic equivalent of Sanofi Genzyme’s Hectorol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials. It is indicated for the treatment of secondary hyperparathyroidism in adult patients with CKD on dialysis. Doxercalciferol Injection (RLD: Hectorol) had an annual sales of approximately $132 million in the U.S. (IQVIA MAT October 2019).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
